ANGIOTECH PHARMACEUTICALS INC 4
4 · ANGIOTECH PHARMACEUTICALS INC · Filed Nov 12, 2009
Insider Transaction Report
Form 4
Cunliffe Sean
SVP, Sales & Marketing
Transactions
- Award
Stock Option with Tandem SAR
2009-11-11+100,000→ 100,000 totalExercise: $1.28From: 2009-12-01Exp: 2014-11-10→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]The options will start to vest effective 12/01/2009 in equal installments on a monthly basis until 11/10/2014.
- [F2]Represents the number of the Company's common shares into which the stock options are convertible. In the event that the Reporting Person elects to exercise the tandem SAR, the stock option will be cancelled and the Reporting Person will be entitled to receive a number of common shares with an aggregate value equal to the product of (a) the excess of the market price of a common share on the date of exercise over the exercise price of the tandem SAR, multipled by (b) the number of tandem SARs exercised.